Growing community of inventors

Tokyo, Japan

Tomoya Miyakawa

Average Co-Inventor Count = 3.17

ph-index = 3

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 16

Tomoya MiyakawaKoji Tamada (11 patents)Tomoya MiyakawaKeiko Udaka (11 patents)Tomoya MiyakawaMasaaki Oka (7 patents)Tomoya MiyakawaShoichi Hazama (7 patents)Tomoya MiyakawaShun Doi (4 patents)Tomoya MiyakawaKeiko Kohasu Udaka (0 patent)Tomoya MiyakawaMorikazu Onji (0 patent)Tomoya MiyakawaMorikazu Onji (0 patent)Tomoya MiyakawaTomoya Miyakawa (15 patents)Koji TamadaKoji Tamada (22 patents)Keiko UdakaKeiko Udaka (13 patents)Masaaki OkaMasaaki Oka (15 patents)Shoichi HazamaShoichi Hazama (11 patents)Shun DoiShun Doi (5 patents)Keiko Kohasu UdakaKeiko Kohasu Udaka (0 patent)Morikazu OnjiMorikazu Onji (0 patent)Morikazu OnjiMorikazu Onji (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Cytlimic Inc. (8 from 8 patents)

2. Nec Corporation (7 from 35,670 patents)

3. Kochi University (4 from 50 patents)

4. Ehime University (45 patents)


15 patents:

1. 12448413 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell

2. 11759518 - Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein

3. 11618770 - MUC1-derived peptide, and pharmaceutical composition for treatment or prevention of cancer, immunity-inducing agent and method for manufacturing antigen presenting cell using same

4. 11491204 - Composition comprising poly I:C and LAG-3-IGG fusion protein

5. 11304997 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell

6. 11291718 - Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein

7. 10875900 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells

8. 10842848 - Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein

9. 10590179 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells

10. 10537626 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell

11. 10526388 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells

12. 9353151 - HLA-binding peptide, and DNA fragment and recombinant vector coding for said HLA-binding peptide

13. 9045531 - HLA-binding peptide, precursor thereof, and DNA fragment and recombinant vector coding for said HLA-binding peptide

14. 8487076 - HLA-binding peptide, and DNA fragment and recombinant vector coding for said HLA-binding peptide

15. 8324345 - HLA-binding peptide, precursor thereof, DNA fragment and recombinant vector encoding the same

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/13/2025
Loading…